Clinical Trial

A Phase 1/2 Trial of ADI-270 in ccRCC

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-25; most recent amendment 2025-08-12.
Status change: Recruiting → Active, Not Recruiting 2025-08-12
Status change: Not Yet Recruiting → Recruiting 2024-11-20
Trial Details
NCT Number NCT06480565
Lead Sponsor Adicet Therapeutics
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 60 participants
Start Date 2024-12-12
Primary Completion 2026-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-15